Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Language
Publication year range
1.
Top Companion Anim Med ; 41: 100475, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32966900

ABSTRACT

This report aims to describe one case of plasma cell pododermatitis associated with feline leukemia virus (FeLV) and concomitant feline immunodeficiency virus (FIV) infection in a cat. A 2-year-old, intact male, mixed-breed cat was presented with alopecia, skin peeling, and erythematous swelling in the left metacarpal paw pad. Swelling, softening, ulceration with secondary crusts, and erythematous to violaceous discoloration were observed in multiple metacarpal, metatarsal, and digital paw pads. Complete blood count and serum biochemistry were analyzed. FeLV antigenemia and FIV seropositivity were assessed by immunoassay (enzyme-linked immunosorbent assay). Nested-PCR was used to detect FIV and FeLV proviral DNA in blood cells. Histopathological examination and anti-FeLV and anti-FIV immunohistochemical were performed on paw pad biopsies. According to clinical and histopathological findings, a diagnosis of plasma cell pododermatitis was made. The cat was FIV and FeLV seropositive. The immunohistochemical of paw pad biopsies revealed FeLV positivity and FIV negativity. This study provides reference for further investigations about feline plasma cell pododermatitis and highlights retrovirus infection as a potential factor associated with this disease.


Subject(s)
Cat Diseases/diagnosis , Feline Acquired Immunodeficiency Syndrome/blood , Foot Dermatoses/veterinary , Retroviridae Infections/veterinary , Tumor Virus Infections/veterinary , Animals , Cat Diseases/virology , Cats , Coinfection/veterinary , Coinfection/virology , Foot Dermatoses/virology , Immunodeficiency Virus, Feline/isolation & purification , Leukemia Virus, Feline/isolation & purification , Male , Plasma Cells , Retroviridae Infections/blood , Tumor Virus Infections/blood
2.
Viruses ; 10(6)2018 05 31.
Article in English | MEDLINE | ID: mdl-29857485

ABSTRACT

Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3 (APOBEC3; A3) proteins comprise an important family of restriction factors that produce hypermutations on proviral DNA and are able to limit virus replication. Vif, an accessory protein present in almost all lentiviruses, counteracts the antiviral A3 activity. Seven haplotypes of APOBEC3Z3 (A3Z3) were described in domestic cats (hap I⁻VII), and in-vitro studies have demonstrated that these proteins reduce infectivity of vif-defective feline immunodeficiency virus (FIV). Moreover, hap V is resistant to vif-mediated degradation. However, studies on the effect of A3Z3 in FIV-infected cats have not been developed. Here, the correlation between APOBEC A3Z3 haplotypes in domestic cats and the frequency of hypermutations in the FIV vif and env genes were assessed in a retrospective cohort study with 30 blood samples collected between 2012 and 2016 from naturally FIV-infected cats in Brazil. The vif and env sequences were analyzed and displayed low or undetectable levels of hypermutations, and could not be associated with any specific A3Z3 haplotype.


Subject(s)
Cytidine Deaminase/genetics , Feline Acquired Immunodeficiency Syndrome/blood , Gene Products, vif/genetics , Genes, env , Immunodeficiency Virus, Feline/genetics , Mutation , Animals , Brazil , Cats/genetics , Feline Acquired Immunodeficiency Syndrome/virology , Haplotypes , Immunodeficiency Virus, Feline/pathogenicity , Proviruses/genetics , Retrospective Studies , Virion/genetics , Virus Replication
3.
Braz. j. infect. dis ; Braz. j. infect. dis;21(1): 35-41, Jan.-Feb. 2017. tab, graf
Article in English | LILACS | ID: biblio-839181

ABSTRACT

Abstract Background: The major complications of “treated” Human Immunodeficiency Virus (HIV) infection are cardiovascular disease, malignancy, renal disease, liver disease, bone disease, and perhaps neurological complications, which are phenomena of the normal aging process occurring at an earlier age in the HIV-infected population. The present study is aimed to explore protein carbonyl content as a biomarker for detecting oxidative DNA damage induced ART toxicity and/or accelerated aging in HIV/AIDS patients. Objective: To investigate the potential of carbonyl content as a biomarker for detecting oxidative Deoxyribonucleic acid (DNA) damage induced Antiretroviral Theraphy (ART) toxicity and/or accelerated aging in HIV/AIDS patients. Methods: In this case–control study a total 600 subjects were included. All subjects were randomly selected and grouped as HIV-negative (control group) (n = 300), HIV-infected ART naive (n = 100), HIV-infected on first line ART (n = 100), and HIV-infected on second line ART (n = 100). Seronegative control subjects were age- and sex-matched with the ART naive patients and the two other groups. Carbonyl protein was determined by the method described in Levine et al. DNA damage marker 8-OH-dG was determined using 8-hydroxy-2-deoxy Guanosine StressXpress ELA Kit by StressMarq Biosciences. Results: Protein carbonyl content levels and oxidative DNA damage were significantly higher (p < 0.05) in HIV-infected patients on second line ART and HIV-infected patients on first line ART than ART naive patients and controls. In a linear regression analysis, increased protein carbonyl content was positively associated with increased DNA damage (OR: 0.356; 95% CI: 0.287–0.426) p < 0.05. Conclusions: Carbonyl content may has a role as a biomarker for detecting oxidative DNA damage induced ART toxicity and/or accelerated aging in HIV/AIDS patients. Larger studies are warranted to elucidate the role of carbonyl content as a biomarker for premature aging in HIV/AIDS patients.


Subject(s)
Humans , Animals , Male , Female , Adult , Middle Aged , Young Adult , DNA Damage/drug effects , Aging/drug effects , Feline Acquired Immunodeficiency Syndrome/blood , Acquired Immunodeficiency Syndrome/drug therapy , Antiretroviral Therapy, Highly Active/adverse effects , Deoxyguanosine/analogs & derivatives , Protein Carbonylation/physiology , Reference Values , Time Factors , DNA Damage/physiology , Aging/metabolism , Enzyme-Linked Immunosorbent Assay , Biomarkers/blood , Case-Control Studies , Age Factors , Acquired Immunodeficiency Syndrome/physiopathology , CD4 Lymphocyte Count , Anti-HIV Agents/adverse effects , Deoxyguanosine/blood
SELECTION OF CITATIONS
SEARCH DETAIL